Epidemiologic differences between women with borderline ovarian tumors and women with epithelial ovarian cancer

Gynecologic Oncology

Volumn 74, Issue 1, 1999, Pages 103-107

  Eltabbakh, Gamal H ^a   Natarajan, Nachimuthu ^a   Piver, M Steven ^a   Mettlin, Curtis J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CLINICAL ARTICLE; FEMALE; HUMAN; ONSET AGE; ORAL CONTRACEPTION; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL;

EID: 0032789380     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5459     Document Type: Article

References (26)

1. Harris R, Whittemore A S, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. Am J Epidemiol. 136:1992;1204-1211.
2. International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand. 50:1971;1-7.
3. Serov, S, F, Scully, R, E, Sobin, L, H, International histologic classification and staging of tumors: histologic typing of ovarian tumors, No. 91, Geneva, Switzerland, World Health Organization, 1973, pp, 37, - 41.
4. Bell D A, Scully R E. Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. Hum Pathol. 21:1990;397-403.
5. Powell D E, Puls L, van Nagell J Jr. Current concepts in epithelial ovarian tumors: does benign to malignant transformation ever occur. Hum Pathol. 23:1992;846-847.
6. Puls L E, Powell D E, DePriest P D, Gallion H H, Hunter J E, Kryscio R J, van Nagell J R Jr. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol. 47:1992;53-57.
7. Bell D A, Scully R E. Early de novo ovarian carcinoma: a study of 14 cases. Cancer. 73:1994;1859-1864.
8. Auranen A, Grenman S, Makinen J, Pukkala E, Sankila R, Salmi T. Borderline ovarian tumors in Finland: epidemiology and familial occurrence. Am J Epidemiol. 144:1996;548-553.
9. Harlow B L, Weiss N S, Roth G J, Chu J, Daling J R. Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous hormones. Cancer Res. 48:1988;5849-5852.
10. Harlow B L, Weiss N S. A case-control study of borderline ovarian tumors: the influence of perineal exposure to talc. Am J Epidemiol. 130:1989;390-394.
11. Eltabbakh G H, Natarajan N, Piver M S, Mettlin C J. Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol. 91:1998;254-259.
12. Gershenson D M, Silva E G. Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer. 65:1990;578-585.
13. Nikrui N. Survey of clinical behavior of patients with borderline ovarian tumors. Gynecol Oncol. 12:1981;107-119.
14. Kliman L, Rome R M, Fortune D W. Low malignant potential tumors of the ovary: a study of 76 cases. Obstet Gynecol. 68:1986;338-344.
15. Bostwick D G, Tazelaar H D, Ballon S C, Hendrickson M R, Kempson R L. Ovarian epithelial tumors of borderline malignancy. Cancer. 58:1986;2052-2065.
16. Whittemore A S, Harris R, Itnyre J. The collaborative ovarian cancer group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol. 136:1992;1184-1203.
17. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case control study. Br J Cancer. 60:1989;592-598.
18. Franceschi S, Parazzini F, Negri E, Booth M, La Vecchia C, Beral V, Tzonou A, Trichopoulos D. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer. 49:1991;61-65.
19. Eltabbakh G H, Belinson J L, Kennedy A W, Biscotti C V, Casey G, Tubbs R R. P53 and HER-2/neu overexpression in ovarian borderline tumors. Gynecol Oncol. 65:1997;218-224.
20. Mok S C, Bell D A, Knapp R C, Fishbaugh P M, Welch W R, Muto M G, Berkowitz R S, Tsao S W. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 53:1993;1489-1492.
21. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. 53:1993;4550-4554.
22. Komitowski D, Janson C, Szamaborski J, Czernobilsky B. Quantitative nuclear morphology in the diagnosis of ovarian tumors of low malignant potential (borderline). Cancer. 64:1989;905-910.
23. Khattech A, Spatz A, Prade M, Duvillard P, Charpentier P, Bognel C, Michel G, Lhomme C. Nucleolar organizer regions in ovarian tumors: discrimination between carcinoma and borderline tumors. Int J Gynecol Pathol. 11:1992;11-14.
24. Nguyen H N, Averette H E, Janicek M. Ovarian carcinoma: a review of the significance of familial risk factors and the role of prophylactic oophorectomy in cancer prevention. Cancer. 74:1994;545-555.
25. Lynch H T, Conway T, Lynch J. Hereditary ovarian cancer pedigree studies: part II. Cancer Genet Cytogenet. 52:1991;161-163.
26. Koch M, Hill G B. Problems in establishing accurate family history in patients with ovarian cancer of epithelial origin. Cancer Detect Prev. 10:1987;279-283.